Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan-Dec:22:15330338221145246.
doi: 10.1177/15330338221145246.

Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review

Boya Lu  1 , Elango Natarajan  1 , Hanumantha Rao Balaji Raghavendran  2 , Uma Devi Markandan  3
Affiliations
Review

Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review

Boya Lu et al. Technol Cancer Res Treat. 2023 Jan-Dec.

Abstract

Breast cancer is the most common malignancy and the second most common cause of cancer-related mortality in women. Triple-negative breast cancers do not express estrogen receptors, progesterone receptors, or human epidermal growth factor receptor 2 and have a higher recurrence rate, greater metastatic potential, and lower overall survival rate than those of other breast cancers. Treatment of triple-negative breast cancer is challenging; molecular-targeted therapies are largely ineffective and there is no standard treatment. In this review, we evaluate current attempts to classify triple-negative breast cancers based on their molecular features. We also describe promising treatment methods with different advantages and discuss genetic biomarkers and other prediction tools. Accurate molecular classification of triple-negative breast cancers is critical for patient risk categorization, treatment decisions, and surveillance. This review offers new ideas for more effective treatment of triple-negative breast cancer and identifies novel targets for drug development.

Keywords: biomarkers; molecular classification; prediction; treatment; triple-negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
(A) Female breast cancer incidence age-standardized rates in specific areas in 2020. (B) Female breast cancer mortality age-standardized rates in specific areas in 2020.
Figure 2.
Figure 2.
Brief summary of the review.
Figure 3.
Figure 3.
BRCA involve in homologous recombination repair (By Figdraw).
See this image and copyright information in PMC

References

    1. Ensenyat-Mendez M, Llinàs-Arias P, Orozco JI, et al. Current triple-negative breast cancer subtypes: Dissecting the most aggressive form of breast cancer. Front Oncol. 2021;11:2311. - PMC - PubMed
    1. Tong CW, Wu M, Cho WC, To KK. Recent advances in the treatment of breast cancer. Front Oncol. 2018;8:227. - PMC - PubMed
    1. Zong Y, Pegram M. Research advances and new challenges in overcoming triple-negative breast cancer. Cancer Drug Resistance. 2021;4(3):517. - PMC - PubMed
    1. Sakach E, O'Regan R, Meisel J, Li X. Molecular classification of triple negative breast cancer and the emergence of targeted therapies. Clin Breast Cancer. 2021;21(6):509-520. - PubMed
    1. Zhao S, Zuo W-J, Shao Z-M, Jiang Y-Z. Molecular subtypes and precision treatment of triple-negative breast cancer. Ann Transl Med. 2020;8(7):499. - PMC - PubMed

MeSH terms